Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Nature Medicine
|
June 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
Max S Topp, Peter Kufer, Nicola Gökbuget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Markus W Löffler, Stefania Gori, Francesco Izzo, et al.
Nature Medicine
|
July 31, 2012
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter, Toni Weinschenk, Arnulf Stenzl, et al.
Nature Medicine
|
April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trial
Martin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Nature Medicine
|
April 29, 2025
Author Correction: Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trial
Martin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Science Translational Medicine
|
August 31, 2022
Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy
Gloria B Kim, Jens Fritsche, Sebastian Bunk, et al.
Cancer Immunology Research
|
May 12, 2023
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, et al.
Nature
|
December 21, 2018
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Nature
|
February 9, 2019
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Nature Medicine
|
June 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
Max S Topp, Peter Kufer, Nicola Gökbuget, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Markus W Löffler, Stefania Gori, Francesco Izzo, et al.
Nature Medicine
|
July 31, 2012
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter, Toni Weinschenk, Arnulf Stenzl, et al.
Nature Medicine
|
April 9, 2025
Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trial
Martin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Nature Medicine
|
April 29, 2025
Author Correction: Autologous T cell therapy for PRAME<sup>+</sup> advanced solid tumors in HLA-A*02<sup>+</sup> patients: a phase 1 trial
Martin Wermke, Dejka M Araujo, Manik Chatterjee, et al.
Science Translational Medicine
|
August 31, 2022
Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy
Gloria B Kim, Jens Fritsche, Sebastian Bunk, et al.
Cancer Immunology Research
|
May 12, 2023
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Apostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, et al.
Nature
|
December 21, 2018
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Nature
|
February 9, 2019
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Page
of 5